摘要: Osteosarcoma (OS), the most common malignant tumor of bone, is presently treated with multidrug neoadjuvant chemotherapy protocols, which allow to cure 60-65% patients but also induce toxicity events that cannot be predicted or efficiently prevented. The identification and validation pharmacogenomic biomarkers is, therefore, absolutely warranted provide bases for planning personalized treatments aim increase therapeutic benefits avoid limit unnecessary toxicities. As several targeted therapies against molecular immunological markers in OS are under clinical investigation, it may speculated some new agents innovative emerge next years. However, real improvement perspectives strictly connected stratify responders non-responders identify those individuals higher susceptibility treatment-associated toxicity. This review provides an overview identified so far OS, appear promising candidates a translation practice, after further investigation and/or prospective validation.
nature.com
elsevier.com
sci-hub.se 参考文章(96)
S Jabeen, L Holmboe, G I G Alnæs, A M Andersen, K S Hall, V N Kristensen, Impact of genetic variants of RFC1, DHFR and MTHFR in osteosarcoma patients treated with high-dose methotrexate Pharmacogenomics Journal. ,vol. 15, pp. 385- 390 ,(2015) , 10.1038/TPJ.2015.11
Rachael E. Windsor, Sandra J. Strauss, Constantinos Kallis, Nicholas E. Wood, Jeremy S. Whelan, Germline genetic polymorphisms may influence chemotherapy response and disease outcome in osteosarcoma Cancer. ,vol. 118, pp. 1856- 1867 ,(2012) , 10.1002/CNCR.26472
William E. Evans, Mary V. Relling, Pharmacogenomics: Translating Functional Genomics into Rational Therapeutics Science. ,vol. 286, pp. 487- 491 ,(1999) , 10.1126/SCIENCE.286.5439.487
Massimo Serra, Michela Pasello, Maria Manara, Katia Scotlandi, Stefano Ferrari, Franco Bertoni, Mario Mercuri, Thor Alvegard, Piero Picci, Gaetano Bacci, Sigbjørn Smeland, May P-glycoprotein status be used to stratify high-grade osteosarcoma patients? Results from the Italian/Scandinavian Sarcoma Group 1 treatment protocol. International Journal of Oncology. ,vol. 29, pp. 1459- 1468 ,(2006) , 10.3892/IJO.29.6.1459
Claudia M. Hattinger, Giuseppina Stoico, Francesca Michelacci, Michela Pasello, Isabella Scionti, Daniel Remondini, Gastone C. Castellani, Marilù Fanelli, Katia Scotlandi, Piero Picci, Massimo Serra, Mechanisms of gene amplification and evidence of coamplification in drug-resistant human osteosarcoma cell lines. Genes, Chromosomes and Cancer. ,vol. 48, pp. 289- 309 ,(2009) , 10.1002/GCC.20640
A Savonarola, R Palmirotta, F Guadagni, F Silvestris, Pharmacogenetics and pharmacogenomics: role of mutational analysis in anti-cancer targeted therapy Pharmacogenomics Journal. ,vol. 12, pp. 277- 286 ,(2012) , 10.1038/TPJ.2012.28
Ilan Ifergan, Issac Meller, Josefin Issakov, Yehuda G. Assaraf, Reduced folate carrier protein expression in osteosarcoma: Implications for the prediction of tumor chemosensitivity Cancer. ,vol. 98, pp. 1958- 1966 ,(2003) , 10.1002/CNCR.11741
Jiawen Teng, Zeng-min Yang, Jie Li, Bo Xu, Predictive role of Glutathione S-transferases (GSTs) on the prognosis of osteosarcoma patients treated with chemotherapy. Pakistan Journal of Medical Sciences. ,vol. 29, pp. 1182- 1186 ,(2013) , 10.12669/PJMS.295.3870
Daniela Caronia, Ana Patiño-Garcia, Antonio Peréz-Martínez, Guillermo Pita, Leticia Tais Moreno, Marta Zalacain-Díez, Blanca Molina, Isabel Colmenero, Luis Sierrasesúmaga, Javier Benítez, Anna Gonzalez-Neira, Effect of ABCB1 and ABCC3 polymorphisms on osteosarcoma survival after chemotherapy: a pharmacogenetic study. PLOS ONE. ,vol. 6, ,(2011) , 10.1371/JOURNAL.PONE.0026091
Cristiane Arruda Dalla-Torre, Silvia Regina Caminada de Toledo, Maisa Yoshimoto, Antônio Sérgio Petrilli, Joyce Anderson Duffles Andrade, Susan Chilton-MacNeill, Jeremy A. Squire, Maria Zielenska, Expression of major vault protein gene in osteosarcoma patients. Journal of Orthopaedic Research. ,vol. 25, pp. 958- 963 ,(2007) , 10.1002/JOR.20371